Clinical efficacy of entecavir therapy and factors associated with treatment response in naive chronic hepatitis B patients / 대한간학회지
The Korean Journal of Hepatology
;
: 446-453, 2009.
Artículo
en Coreano
| WPRIM
| ID: wpr-161895
ABSTRACT
BACKGROUND/AIMS:
Entecavir is a potent and selective guanosine analogue that has demonstrated a significant antiviral efficacy against hepatitis B virus (HBV). The aim of this study was to characterize the response to entecavir and to examine the factors affecting that response.METHODS:
We administered 0.5 mg of entecavir once daily for more than 12 months to 114 naive chronic hepatitis B (CHB) patients. We measured the levels of liver enzymes, serological markers, and serum HBV DNA at 3-month interval.RESULTS:
Normalization of serum alanine aminotransferase levels was observed in 68.5% (76/114), 74.6% (85/114), and 81.6% (62/76) of patients after 6, 12, and 24 months of therapy, respectively. HBV DNA levels of <50 copies/mL (as evaluated by polymerase chain reaction) were observed in 43.9% (50/114), 71.1% (81/114), and 85.5% (65/76) of patients after 6, 12, and 24 months, respectively. Viral breakthrough was not observed. The rates of HBeAg loss and seroconversion were 43.5% (27/62) and 14.5% (9/62), respectively, after 12 months of therapy, and 56.4% (22/39) and 15.4% (6/39) after 24 months. The independent factor associated with PCR negativity was early virologic response (EVR; HBV DNA <2,000 copies/mL after 3 months of therapy, P<0.001). The independent factors predicting HBeAg loss were found to be serum albumin levels (P=0.041) and EVR (P=0.005).CONCLUSIONS:
Entecavir induced excellent biochemical and virologic responses in naive CHB patients. EVR was an independent factor for predicting HBV PCR negativity and HBeAg loss.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Antivirales
/
Aspartato Aminotransferasas
/
Factores de Tiempo
/
ADN Viral
/
Reacción en Cadena de la Polimerasa
/
Estudios Retrospectivos
/
Hepatitis B Crónica
/
Alanina Transaminasa
/
Guanina
/
Antígenos e de la Hepatitis B
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
/
Factores de riesgo
Límite:
Adulto
/
Femenino
/
Humanos
/
Masculino
Idioma:
Coreano
Revista:
The Korean Journal of Hepatology
Año:
2009
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS